JP2024540937A5 - - Google Patents

Info

Publication number
JP2024540937A5
JP2024540937A5 JP2024523615A JP2024523615A JP2024540937A5 JP 2024540937 A5 JP2024540937 A5 JP 2024540937A5 JP 2024523615 A JP2024523615 A JP 2024523615A JP 2024523615 A JP2024523615 A JP 2024523615A JP 2024540937 A5 JP2024540937 A5 JP 2024540937A5
Authority
JP
Japan
Prior art keywords
fibrosis
lpa
pharmaceutically acceptable
disease
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523615A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540937A (ja
Filing date
Publication date
Priority claimed from PCT/CN2021/125409 external-priority patent/WO2022083703A1/en
Application filed filed Critical
Priority claimed from PCT/CN2022/126596 external-priority patent/WO2023066359A1/en
Publication of JP2024540937A publication Critical patent/JP2024540937A/ja
Publication of JP2024540937A5 publication Critical patent/JP2024540937A5/ja
Pending legal-status Critical Current

Links

JP2024523615A 2021-10-21 2022-10-21 Ｌｐａ受容体活性に関連する状態を処置するための化合物および組成物 Pending JP2024540937A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/125409 2021-10-21
PCT/CN2021/125409 WO2022083703A1 (en) 2020-10-22 2021-10-21 Compounds and compositions for treating conditions associated with lpa receptor activity
CNPCT/CN2022/082072 2022-03-21
CN2022082072 2022-03-21
PCT/CN2022/126596 WO2023066359A1 (en) 2021-10-21 2022-10-21 Compounds and compositions for treating conditions associated with lpa receptor activity

Publications (2)

Publication Number Publication Date
JP2024540937A JP2024540937A (ja) 2024-11-06
JP2024540937A5 true JP2024540937A5 (cg-RX-API-DMAC7.html) 2025-10-27

Family

ID=86057939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523615A Pending JP2024540937A (ja) 2021-10-21 2022-10-21 Ｌｐａ受容体活性に関連する状態を処置するための化合物および組成物

Country Status (5)

Country Link
US (1) US20240400562A1 (cg-RX-API-DMAC7.html)
EP (1) EP4419509A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540937A (cg-RX-API-DMAC7.html)
CN (1) CN118339149A (cg-RX-API-DMAC7.html)
WO (1) WO2023066359A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820682B2 (en) * 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
AR108838A1 (es) * 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
KR102623218B1 (ko) * 2018-08-23 2024-01-11 가천대학교 산학협력단 페닐아세트산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
EP4058144A1 (en) * 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CN116583501A (zh) * 2020-10-22 2023-08-11 罗特斯生物公司 用于治疗与lpa受体活性相关的病症的化合物和组合物

Similar Documents

Publication Publication Date Title
JP2021508686A5 (cg-RX-API-DMAC7.html)
JP6931019B2 (ja) 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
HRP20211918T1 (hr) Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
JP2021502358A5 (cg-RX-API-DMAC7.html)
ES2281978T3 (es) Uso de un antagonista del receptor at-1 o de un modulador del receptor at-2 para tratar enfermedades asociadas con un incremento de los receptores at-1 o at-2.
JP2021063119A (ja) 噴霧乾燥製剤
JP2022500470A5 (cg-RX-API-DMAC7.html)
TW201639571A (zh) 非酒精性脂肪肝病以及/或脂質營養不良症之治療方法
JP2021522249A5 (cg-RX-API-DMAC7.html)
JP2020508302A5 (cg-RX-API-DMAC7.html)
JP2021507895A5 (cg-RX-API-DMAC7.html)
CA2511843A1 (en) Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
JP2018048154A (ja) 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
JP2022500473A5 (cg-RX-API-DMAC7.html)
JP2008540672A (ja) 病状に起因する性的機能不全の治療方法
JP2022500469A5 (cg-RX-API-DMAC7.html)
JP2006523216A5 (cg-RX-API-DMAC7.html)
JP2015511609A5 (cg-RX-API-DMAC7.html)
JP2024540937A5 (cg-RX-API-DMAC7.html)
JP2002533390A5 (cg-RX-API-DMAC7.html)
JP2022501327A5 (cg-RX-API-DMAC7.html)
JP2023065454A5 (cg-RX-API-DMAC7.html)
JP2022169780A5 (cg-RX-API-DMAC7.html)
JP2021534160A5 (cg-RX-API-DMAC7.html)
WO2019119832A1 (zh) 用于代谢性疾病治疗的化合物及其制备方法和应用